Quoin Pharmaceuticals (2EB0) Stock Statistics & Valuation Metrics
Total Valuation
Quoin Pharmaceuticals has a market cap or net worth of EUR 19.46M. The enterprise value is -EUR 1.08M.
- Market Cap
- EUR 19.46M
- Enterprise Value
- -EUR 1.08M
Share Statistics
Quoin Pharmaceuticals has 4,804,161 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 4,804,161
- Owned by Insiders
- 3.80%
- Owned by Institutions
- 32.55%
Financial Efficiency
Quoin Pharmaceuticals’s return on equity (ROE) is -1.20 and return on invested capital (ROIC) is -109.75%.
- Return on Equity (ROE)
- -1.20
- Return on Assets (ROA)
- -0.78
- Return on Invested Capital (ROIC)
- -109.75%
- Return on Capital Employed (ROCE)
- -1.10
- Revenue Per Employee
- 0
- Profits Per Employee
- -3.95M
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Quoin Pharmaceuticals is -0.30. Quoin Pharmaceuticals’s PEG ratio is -0.00.
- PE Ratio
- -0.30
- PS Ratio
- 0.00
- PB Ratio
- 2.32
- Price to FCF
- -0.59
- Price to Operating Cash Flow
- -0.59
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Quoin Pharmaceuticals had revenue of 0 and earned -15.80M in profits. Earnings per share was -10.63.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -16.29M
- Pretax Income
- -15.80M
- Net Income
- -15.80M
- EBITDA
- -15.70M
- Earnings Per Share (EPS)
- -10.63
Cash Flow
In the last 12 months, operating cash flow was -15.39M and capital expenditures 1, giving a free cash flow of -15.39M billion.
- Operating Cash Flow
- -15.39M
- Free Cash Flow
- -15.39M
- Free Cash Flow per Share
- -7.66
Dividends & Yields
Quoin Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -168.80%
- Earnings Yield
- -205.72%
Stock Price Statistics
- Beta
- -0.11
- 52-Week Price Change
- -61.40%
- 50-Day Moving Average
- 4.52
- 200-Day Moving Average
- 4.85
- Relative Strength Index (RSI)
- 52.38
- Average Volume (3m)
- 216
Important Dates
Quoin Pharmaceuticals upcoming earnings date is Nov 05, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Quoin Pharmaceuticals as a current ratio of 3.61, with Debt / Equity ratio of 0.00%
- Current Ratio
- 3.61
- Quick Ratio
- 3.61
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 243.12
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Quoin Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Quoin Pharmaceuticals EV to EBITDA ratio is -0.28, with an EV/FCF ratio of -0.34.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.28
- EV to Free Cash Flow
- -0.34
- EV to Operating Cash Flow
- -0.34
Balance Sheet
Quoin Pharmaceuticals has EUR 10.80M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 10.80M billion.
- Cash & Marketable Securities
- EUR 10.80M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 10.80M
- Net Cash Per Share
- EUR 2.25
- Tangible Book Value Per Share
- EUR 1.79
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Quoin Pharmaceuticals is EUR 19.10, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 19.10
- Price Target Upside
- 394.75% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―